Re: Q2 Zenith/Resverlogix Events
in response to
by
posted on
Apr 12, 2016 05:10PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Hi Sanfran.
I share your frustration but in my mind Don laid out the plan in his presentation on Jan 7th. He said it's a long term plan (specifically 3 years). The prostate trial is supposed to start in April and will last until the spring of 2018. If the results are positive at that time then there could be value in an IPO. As I posted on SH I also remember that since this trial is not double blind they will be monitoring it continuously or at intervals and thus can look at survival rates and other tests related to their hypothesis and I guess compare against expectations. Positive results (i.e. patients not dying) on this could fuel perceived value in Zenith earlier than the end of the trial and hence excitment in an IPO. Let's hope they get blockbuster results. As Don stated cancer drug progress moves much faster than cardio.
As per BDAZ's post they have lots of communications activities happening so the message may spark interest. They also seem to have excellent scientists on board and a range of potential including CKD. So these actiivities will help fuel interest in the potential for epigenetics and particularly BET inhibitors.
Don did indicate there would be an IPO via a reverse takeover of a company that already has a TSX and/or NASDAQ listing(s). He also said that interested suitors could write a cheque for RVX or Zenith or both and he did indicate there were 2 interested parties at this stage (I believe that this related to the next regional deal for RVX???). Of course Don will be holding out for big $.
So IMHO unless there is a significant material event I don't think you will hear from Don on Zenith until January of 2017.
Of course I have no inside information so I have developed my opinions based on observing the last 8 years. In this regard I will say that communications began to improve at the stage of RVX announcing their post hoc findings on rvx-208 when they begain to understand more about the MOA of rvx-208.
Regular updates would not be difficult for them to do and would greatly enhance confidence but they are still in the dark ages on the issue of communications.
GLTA
Toinv